Immutep is a clinical-stage biotechnology company at the forefront of developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.

Access recent press releases, investor updates, in-depth analyst reports and all the latest news from biotechnology company Immutep.

View the current Immutep clinical oncology pipeline and discover how our immunotherapy technology is being used for autoimmune and cancer treatments.

Immutep Ltd (formerly Prima Biomed) is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech.

2024年12月13日 · Efti是Immutep的专有可溶性LAG-3蛋白和MHC II类激动剂，通过刺激先天和适应性免疫来治疗癌症。作为首个抗原呈递细胞（APC）激活剂，efti能够结合MHC II类分子，激活并促进CD8+细胞毒性T细胞、CD4+辅助T细胞、树突细胞、NK细胞和单核细胞的增殖。

2023年6月11日 · 在2023 ASCO会议期间，Immutep、信达、复宏汉霖等企业更新了旗下LAG-3药物的最新进展。 LAG-3作为“免疫治疗2.0”中的热门靶点，研发一开始却屡屡碰壁，直到2018年华人科学家陈列平找到了LAG-3的配体FGL1，为靶向LAG-3的免疫治疗进一步打下了理论基础。

2021年8月5日 · AIPAC（Active Immunotherapy Paclitaxel）是一项针对HER2-/HR+转移性乳腺癌的多中心、安慰剂对照、双盲、1:1随机IIb期临床试验。旨在评估Immutep的主要候选产品eftilagimod alpha（efti，LAG-3Ig或IMP321）与紫杉醇化疗的联合应用，指征HER2-/HR+ 转移性乳腺癌（HR+MBC）。227例HER2-/HR+ ...

2025年4月1日 · Shares in Immutep have leapt after the biotech reported phase 2b results showing that LAG-3 inhibitor eftilagimod alfa (efti) significantly boosted the efficacy of MSD’s Keytruda in patients ...

2025年3月9日 · Immutep (ASX:IMM) CEO Marc Voigt discusses the company’s latest advancements in immunotherapy and autoimmune treatments. A key focus is the TACTI-004 trial, a large-scale Phase III study for first-line non-small cell lung cancer, conducted in collaboration with Merck, across more than 25 countries.

2023年5月1日 · 了解Immutep SAS (Immutep SAS)公司的药物管线，治疗领域，技术平台，以及它的14项临床试验, 9篇新闻，疾病领域:肿瘤，内分泌与代谢疾病，免疫系统疾病，神经系统疾病，血液及淋巴系统疾病，感染，技术平台:单克隆抗体，融合蛋白，药物:重组人源淋巴细胞激活 ...